新元資本旗下基金向Sanofi出售Kymab項目 涉資最少11億美元
新元資本宣布,新元一期基金與Sanofi(SNY.US)於本周一(11日)達成協議,出售其於臨床階段生物製藥公司Kymab之權益予賽諾菲。作為代價,賽諾菲將支付11億美元首期付款、及在達成某些裡程碑後支付額外最多3.5億美元,予退出Kymab的投資者。上述交易預計於2021年上半年完成。同時,新元資本今天亦宣布完成其新元二期基金之首輪募集。
Kymab為新元一期基金最大的投資項目,基金與海普瑞(09989.HK)共同領投了Kymab於2016年11月完成的C輪優先股融資,新元一期基金其後在2019年和2020年先後對Kymab進行了後續投資。
Kymab是一家成立於2010年的臨床階段的英國生物製藥公司,透過其專有的集成平台IntelliSelect,開發全人源化單克隆抗體治療劑,並專注於免疫介導的疾病和免疫腫瘤學。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.